Laura K. Fishwick

Representative Matters

• Represented Novartis in Novartis v. Breckenridge, West-Ward and Par (Zortress® (everolimus) for kidney and liver transplants) (D. Del., Fed. Cir., PTAB-IPR)
• Represented Novartis in Novartis v. West-Ward (Afinitor® (everolimus) for renal cell carcinoma and pancreatic neuroendocrine tumors) (D. Del., Fed. Cir., PTAB-IPR)
• Represented Novartis in Novartis v. Par (Afinitor® (everolimus) for breast cancer) (D. Del.)
• Represented Novartis in Novartis v. Breckenridge (Afinitor® (everolimus) for renal cell carcinoma, renal angiomyolipoma, and tuberous sclerosis complex with subependymal giant cell astrocytoma) (D. Del., PTAB-IPR)
• Represented Novartis in Novartis v. Mylan (Afinitor® Disperz (everolimus) for tuberous sclerosis complex with subependymal giant cell astrocytoma) (D. Del.)

Representative Clients

• Novartis

Education

• J.D. Harvard Law School 2013
• • Digest submissions editor, Harvard Journal of Law and Technology
• B.S. Biochemistry and Molecular Biology summa cum laude University of Florida 2010

Bar Admissions

• New York
• U.S. Patent and Trademark Office

Court Admissions

• Southern District of New York
• U.S. Court of Appeals for the Federal Circuit

• The Best Lawyers in America, Ones to Watch, 2021 – 2022